Innovent Signs $45 Million Deal to Commercialize Two Lilly Oncology Drugs in China
publication date: Mar 28, 2022
Suzhou Innovent Bio acquired China commercialization rights for two Lilly oncology drugs and the right of first negotiation to a third candidate. Innovent will make $45 million in payments once the first two drugs are approved for China use. In the agreement, Innovent acquired rights to Cyramza® (ramucirumab), a China-approved gastric cancer therapy, and Retsevmo® (selpercatinib), with a China NDA for NSCLC under review. The third drug is a BTK inhibitor aimed at leukemia and lymphoma. In 2015, Lilly and Innovent formed a $1 billion partnership for Innovent’s novel drugs. More details....
Stock Symbols: (HK: 01801) (NYSE: LLY)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.